Metabolic syndrome - ways to the development of oncopathology

Authors

  • Mikhail A Osadchuk Federal State Autonomous Educational Institution of Higher Education I.M. Sechenov First Moscow State Medical University of the Ministry of Health of the Russian Federation (Sechenov University), Moscow, Russian Federation
  • Olga I Mitrokhina Federal State Autonomous Educational Institution of Higher Education I.M. Sechenov First Moscow State Medical University of the Ministry of Health of the Russian Federation (Sechenov University), Moscow, Russian Federation
  • Maxim V Trushin Kazan Federal University, Kazan, Russia
  • Inna N Vasileva Federal State Autonomous Educational Institution of Higher Education I.M. Sechenov First Moscow State Medical University of the Ministry of Health of the Russian Federation (Sechenov University), Moscow, Russian Federation

DOI:

https://doi.org/10.3329/bjms.v24i2.81727

Keywords:

metabolic syndrome; oncological diseases; arterial hypertension; hyperglycemia; dyslipidemia

Abstract

Objectives To determine the probability of developing oncological pathology in individuals with metabolic syndrome (MS) and compare the results with the frequency of tumor development in patients without MS by conducting a retrospective cohort study. Methods This observational retrospective study was conducted between April 2021 and September 2023. According to outpatient charts, the incidence of oncological diseases in 994 patients with MS lasting more than 10 years, and the degree of dependence on its components: abdominal obesity (AO), arterial hypertension (AH), carbohydrate metabolism disorders, dyslipidemia were analyzed1. According to the same parameters, the data of 999 patients without MS who made up the comparison group were analyzed. By the method of cross-tabulation, the odds ratios (OR) of carcinogenesis and 95% confidence intervals (95% CI) were estimated. The SPSS 22.0 program is used for statistical processing of the results of the study. Results The study made it possible to conclude that if a patient has MS, the ten-year risk of developing oncopathology is almost three times higher than in its absence (with MS, an oncoprocess was detected in every 5th patient, in its absence in every 14th). AO, especially grade I, is a risk factor for cancer of various localization. It was revealed that hypertension is a universal risk factor for cancer and aggravates the course of oncological diseases in combination with MS. An important role in the development of cancer processes is played by the age of the patient1. Analysis of the data obtained indicates a decrease in the risk of cancer in people with MS with impaired tolerance to carbohydrates taking metformin. Conclusion MS is a risk factor for the development of oncological diseases of any localization. AO, as the main criterion of MS, is associated with an increased risk of carcinogenesis. Hypertension is the main risk factor for the development of oncological diseases, regardless of the presence or absence of MS.

Bangladesh Journal of Medical Science Vol. 24 No. 02 April’25 Page : 598-605                            

Downloads

Abstract
129
PDF
43

Downloads

Published

2025-05-17

How to Cite

Osadchuk, M. A., Mitrokhina, O. I., Trushin, M. V., & Vasileva, I. N. (2025). Metabolic syndrome - ways to the development of oncopathology. Bangladesh Journal of Medical Science, 24(2), 598–605. https://doi.org/10.3329/bjms.v24i2.81727

Issue

Vol. 24 No. 2 (2025)

Section

Original Articles

License

Copyright (c) 2025 Mikhail A Osadchuk, Olga I Mitrokhina, Maxim V Trushin, Inna N Vasileva

Creative Commons License

This work is licensed under a Creative Commons Attribution 4.0 International License.

Authors who publish in the Bangladesh Journal of Medical Science agree to the following terms that:

  1. Authors retain copyright and grant Bangladesh Journal of Medical Science the right of first publication of the work.

  2. Creative Commons Licence
    Articles in Bangladesh Journal of Medical Science are licensed under a Creative Commons Attribution 4.0 International License CC BY-4.0.This license permits use, distribution and reproduction in any medium, provided the original work is properly cited.
  3. Authors are able to enter into separate, additional contractual arrangements for the distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgement of its initial publication in this journal.
  4. Authors are permitted to post their work online (e.g., in institutional repositories or on their website) as it can lead to productive exchanges, as well as greater citation of published work.